Clinical trials
Hormone Receptor Negative Breast Carcinoma clinical trials
Below are recruiting hormone receptor negative breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 129 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06227117RecruitingPhase 2
Study of DV and Toripalimab before surgery for HER2-low breast cancer
This trial tests a combination of two drugs (DV and Toripalimab) with chemotherapy before surgery for a specific type of breast cancer (HER2-low, HR-negative) that has not spread too far. The goal is to see if this approach can shrink the tumor and improve outcomes.
Changsha, HunanAges 18 years+ - NCT07043725RecruitingPhase 3
Neoadjuvant TQB2102 for HER2-positive breast cancer
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
Bengbu, AnhuiAges 18–75 - NCT07369505RecruitingPhase 1
A study of Sapu003 for advanced tumors sensitive to mTOR
This trial tests a new drug, Sapu003, in people with certain advanced cancers that may respond to mTOR-targeted therapy. It is looking at two groups: postmenopausal women with a type of breast cancer (HR+/HER2-), and adults with kidney, liver, neuroendocrine, or TSC-related tumors. The goal is to see if Sapu003 is safe and effective.
AdelaideAges 18 years+ - NCT07661927RecruitingPhase 2
Skipping hormone therapy for low-risk breast cancer
This trial tests whether women with very low-risk, early-stage breast cancer can safely skip hormone therapy after surgery. It is designed for women who are 60 or older and whose cancer shows no spread to lymph nodes and has favorable biology.
AngersAges 60 years+ - NCT06369831RecruitingPhase 2
Imaging test for HER2 in metastatic cancer
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Innsbruck, TyrolAges 18 years+ - NCT06218303RecruitingPhase 1
Vaccine for early breast cancer (DCIS)
This trial tests a vaccine that targets a protein (MUC1) found in early breast cancer cells. It's for women with ER+ DCIS who are planning surgery, to see if the vaccine can help prevent the cancer from coming back or getting worse.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+
Hear when a new Hormone Receptor Negative Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hormone receptor negative breast carcinoma?
- Yes. Clin2 currently lists 129 recruiting hormone receptor negative breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hormone receptor negative breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hormone receptor negative breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hormone Receptor Positive Breast Carcinoma
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Metastatic Hormone Receptor-Positive Breast Carcinoma
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Hormone-receptor-positive Breast Cancer
- HER2-Negative Breast Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Early Stage Triple-Negative Breast Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.